Investigational osteoporosis drug, abaloparatide, lowers fracture risk

Abaloparatide-SC, an injectable drug being studied for the treatment of postmenopausal osteoporosis, reduces the rate of new spinal fractures by a statistically significant 86 percent and as well as statistically significant reductions in the fracture rate at other parts of the body, a phase 3 clinical trial finds. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *